HMGA2 IOD values were also much higher in stage I cervical cancer than in CINIII samples (Figure 2F and Table 2, 136380.20 vs. 9813.53, P < 0.01); no other significant differences were observed between successive stages of CIN and cervical cancer (Figure 2F; normal vs. CINI, P = 0.589; CINI vs. CINII, P = 0.286; CINII vs. CINIII, P = 0.962; stage I vs. stage II cervical cancer, P = 0.791). Here, HMGA2 is linked to uterine cervix carcinoma in situ.